» Articles » PMID: 20126616

Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems

Overview
Journal PLoS One
Date 2010 Feb 4
PMID 20126616
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen ablation therapy is currently the primary treatment for metastatic prostate cancer. Unfortunately, in nearly all cases, androgen ablation fails to permanently arrest cancer progression. As androgens like testosterone are withdrawn, prostate cancer cells lose their androgen sensitivity and begin to proliferate without hormone growth factors. In this study, we constructed and analyzed a mathematical model of the integration between hormone growth factor signaling, androgen receptor activation, and the expression of cyclin D and Prostate-Specific Antigen in human LNCaP prostate adenocarcinoma cells. The objective of the study was to investigate which signaling systems were important in the loss of androgen dependence. The model was formulated as a set of ordinary differential equations which described 212 species and 384 interactions, including both the mRNA and protein levels for key species. An ensemble approach was chosen to constrain model parameters and to estimate the impact of parametric uncertainty on model predictions. Model parameters were identified using 14 steady-state and dynamic LNCaP data sets taken from literature sources. Alterations in the rate of Prostatic Acid Phosphatase expression was sufficient to capture varying levels of androgen dependence. Analysis of the model provided insight into the importance of network components as a function of androgen dependence. The importance of androgen receptor availability and the MAPK/Akt signaling axes was independent of androgen status. Interestingly, androgen receptor availability was important even in androgen-independent LNCaP cells. Translation became progressively more important in androgen-independent LNCaP cells. Further analysis suggested a positive synergy between the MAPK and Akt signaling axes and the translation of key proliferative markers like cyclin D in androgen-independent cells. Taken together, the results support the targeting of both the Akt and MAPK pathways. Moreover, the analysis suggested that direct targeting of the translational machinery, specifically eIF4E, could be efficacious in androgen-independent prostate cancers.

Citing Articles

Toward a genome scale sequence specific dynamic model of cell-free protein synthesis in .

Horvath N, Vilkhovoy M, Wayman J, Calhoun K, Swartz J, Varner J Metab Eng Commun. 2020; 10:e00113.

PMID: 32280586 PMC: 7136494. DOI: 10.1016/j.mec.2019.e00113.


Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.

Kwegyir-Afful A, Ramalingam S, Ramamurthy V, Purushottamachar P, Murigi F, Vasaitis T Cancers (Basel). 2019; 11(11).

PMID: 31653008 PMC: 6895912. DOI: 10.3390/cancers11111637.


Reduced order modeling and analysis of the human complement system.

Sagar A, Dai W, Minot M, LeCover R, Varner J PLoS One. 2017; 12(11):e0187373.

PMID: 29155837 PMC: 5695804. DOI: 10.1371/journal.pone.0187373.


JuPOETs: a constrained multiobjective optimization approach to estimate biochemical model ensembles in the Julia programming language.

Bassen D, Vilkhovoy M, Minot M, Butcher J, Varner J BMC Syst Biol. 2017; 11(1):10.

PMID: 28122561 PMC: 5264316. DOI: 10.1186/s12918-016-0380-2.


Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting.

Kumar R Asian J Androl. 2016; 18(5):682-6.

PMID: 27364545 PMC: 5000788. DOI: 10.4103/1008-682X.183380.


References
1.
Tam L, McGlynn L, Traynor P, Mukherjee R, Bartlett J, Edwards J . Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer. 2007; 97(3):378-83. PMC: 2360337. DOI: 10.1038/sj.bjc.6603871. View

2.
Richter J, Sonenberg N . Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005; 433(7025):477-80. DOI: 10.1038/nature03205. View

3.
Canil C, Moore M, Winquist E, Baetz T, Pollak M, Chi K . Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005; 23(3):455-60. DOI: 10.1200/JCO.2005.02.129. View

4.
Los M, Maddika S, Erb B, Schulze-Osthoff K . Switching Akt: from survival signaling to deadly response. Bioessays. 2009; 31(5):492-5. PMC: 2954189. DOI: 10.1002/bies.200900005. View

5.
Culig Z, Hobisch A, Cronauer M, Radmayr C, Trapman J, HITTMAIR A . Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994; 54(20):5474-8. View